TCS Named a Leader in IDC MarketScape for Supply Chain Oracle Ecosystems Services
Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has been positioned as a Leader in the IDC MarketScape for Worldwide Supply Chain Oracle Ecosystems Services
According to the report, “TCS SCM services are deeply rooted in Ecosystem Thought Leadership and delivered in a consulting-led approach that leverages its extensive digital capabilities.” It goes on to say that “Manufacturers in industries such as automotive, high tech, heavy machinery, and life sciences with a focus on application development, systems implementation, or business process outsourcing should consider TCS when looking for a partner that can drive Oracle Supply Chain Management (SCM) value and supply chain transformation on a global scale.”
TCS’ Oracle supply chain ecosystem solutions drive both value definition and value realization for clients. Its solutions span across technology, key horizontals, and the major functions of the supply chain. TCS utilizes best of breed Oracle applications, leverages digital capabilities, and incorporates industry-leading practices and standards into its solutions. TCS’ 360-degree partnership with Oracle is built on a powerful framework of co-innovation and delivery, and transforms its clients’ supply chains using framework-based business solutions.
The TCS Enterprise Navigator™ framework includes assessment tools, industry benchmarking, change management, location independent agile, TCS PACE™ and intelligent enterprise related accelerators such as MFDM™, BizDevOps tools and process monitoring dashboards. TCS’ large team of global Oracle practitioners bring contextual knowledge, domain, industry, and product expertise to drive Oracle-enabled solutions across the supply chain.
TCS’ Supply Chain practice envisions, designs, and builds digital enterprise supply networks which are adaptive, non-linear, omnidirectional, real-time sense and respond networks. TCS is advising, designing, and creating supply chain strategies for customers to operate in today’s environment while thinking and building for the future.
TCS’ Oracle services portfolio encompasses interactive design, advisory, consulting and implementation services. The company helps customers evaluate digital offerings across SaaS, PaaS and IaaS and define their roadmap including architecture and strategy for modernization and innovation. TCS’ pre-configured industry solutions provide an insight-driven and digitally integrated platform to accelerate customer
Sonata Software celebrates 30 years of relationship with Microsoft
Sonata Software Ltd., a global IT services and technology solutions company, announced 30 years of relationship with Microsoft, and a commitment to invest aggressively in a business that Sonata had identified ahead of the curve and has helped drive growth. A relationship that started in India in 1991 has today blossomed into a worldwide 360-degree one, spanning industries, technologies and geographies. Currently Sonata not only provides services to Microsoft across product engineering, customer support and internal IT applications, but has a deep global relationship across continents, industries and services being a global ISV, SI, lSP, CSP and ISV dev centre.
For Sonata, the key to this success has been aligning continuously to Microsoft’s strategy and making investments proactively, organically and inorganically. Today the Sonata global go-tomarket strategy based on its proprietary digital transformation concept – PlatformationTM, is totally aligned to the Microsoft digital transformation strategy of engaging customers, empowering employees, optimizing operations, and transforming products across the pillars of modern work, Applications and infrastructure, Data & AI and business applications. This has been done through a variety of initiatives from working closely with product engineering teams of Microsoft to leverage the knowledge for building deep expertise, build industryleading technology practices around platform engineering on Azure and Dynamics 365, providing engineering services to ISVs wanting to migrate to the Microsoft platform.
Talking about Sonata’s expertise in taking Microsoft offerings to market, PVSN Raju, Chief Delivery Officer, Sonata Software, said “Sonata is certified across 18 Microsoft offerings, and is now among a select list of global partners that have achieved specialised accreditation across many of these, which are critical to Microsoft’s growth plans, like Windows Virtual Desktop and Azure certifications.”
Sonata started early in identifying a growth opportunity in Microsoft technologies and to create differentiation, has been investing in acquisitions, IP Development, Industry specialisation, Global and Local Partnerships and New Geo and Market Expansion.
In 2015 Sonata expanded its footprint in the Microsoft Dynamics 365 ecosystem with I.B.I.S.’s leading supply chain software and services provider, renowned for its proprietary Advanced Supply Chain Software solution. Sonata established its first US development facility in Redmond to get closer to Microsoft and enable deeper engagement and entered into a partnership with a Denmark–based consulting firm to implement end-to-end Dynamics 365 solutions in the region. The recent strategic acquisition of Australia-based Scalable Data Systems and US-based Sopris Systems, has significantly augmented their Microsoft Dynamics 365 capabilities across the areas of F&O and Field Service, respectively. Scalable Data Systems’ IP for the Commodities Trading Industry and Sopris’ capabilities in Field Service, one of the fastest growing areas of Dynamics 365 has helped in taking Microsoft solutions to customers in newer segments.
Nestlé India continues its unwavering support to the communities, to setup Oxygen Plants in five hospitals near our factory locations
Mr. Suresh Narayanan, Chairman and Managing Director, Nestlé India: “In times like these, as we see the impact of the pandemic on the communities around us, it is our strong values and purpose as a company that drives us to overcome our personal suffering and heed to a societal call of duty. I am immensely proud that my team is continuing to help those communities in need during the pandemic, with initiatives that focus on safeguarding the wellbeing of people at large. We have lent a helping hand in augmenting much needed medical supplies like ventilators, masks, PPE kits, face shields, oximeters etc. We are also connecting with over 90,000 nurses and helpers across 198 hospitals in India to express our heartfelt gratitude for their selfless service to humanity by humbly sharing product hampers. Recognizing the need for oxygen support for COVID patients, my team is in the process of setting up oxygen plants in five hospitals near our factory locations in Punjab, Himachal Pradesh, Uttarakhand, Karnataka and Goa. We will continue to contribute to Akshaya Patra’s COVID-19 relief operations, which has already helped serve over 2 million cooked meals. Further, till now, over 50,000 ration kits for families in need have been provided across various locations in India and we will continue to accelerate this initiative. We have received overwhelming solidarity from our colleagues globally, with Nestlé S.A also extending support in these times of need and providing oxygen concentrators directly and through International Federation of Red Cross and Red Crescent Societies. As a proud citizen of this nation and as the head of the Nestlé India family, I remain optimistic that together we shall overcome this grave health crisis.”
Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe
Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, the generic version of Firazyr®1 Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe, of Shire Human Genetic Therapies, Inc. This marks Glenmark’s first synthetic decapeptide injectable approval and will be manufactured in their North American manufacturing facility based in Monroe, North Carolina.
According to IQVIATM sales data for the 12 month period ending March 2021, the Firazyr® Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe market2 achieved annual sales of approximately $223.4 million*.
Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India
Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk* of severe COVID19
Roche India and Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers. The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries
“Roche is deeply committed to support the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalisation, ease the burden on healthcare systems and play a key role in treatment of high risk patients before their condition worsens,” said V. Simpson Emmanuel, Managing Director and CEO, Roche Pharma India.
The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk* of developing severe COVID-19 disease and do not require oxygen. It has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70% and shortening the duration of symptoms by four days
Zydus launches Ujvira (Trastuzumab Emtansine), a breakthrough in Breast Cancer treatment
Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name ‘Ujvira’. HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25% of all Breast Cancers.
In a step that can significantly reduce treatment cost by almost 80%, the drug is being offered at Rs. 32495 for a 100 mg vial. The current MRP of existing Trastuzumab Emtansine drug is Rs. 1,59,225 for 100 mg vial. Ujvira will be available in two strengths, 100 mg and 160 mg.
Speaking on this milestone, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, “The launch of Ujvira reinforces the innovation capabilities that India has to be able to create complex therapies like ADCs and Zydus' ongoing commitment to offer breakthroughs backed by science and innovation. This research breakthrough enables access to a critical drug for patients who are undergoing therapy for Breast Cancer. We hope that with this innovation, patients will be able to adhere to the treatment and stand to benefit from the advanced technology without worrying about the cost of the treatment.”
Trastuzumab Emtansine ADC biosimilar is developmental breakthrough due to its complexity in manufacturing and similarity assays. This drug is made by combining Trastuzumab and a cytotoxic compound Emtansine (DM1) with the help of a stable linker by a process called Antibody Drug Conjugation. Due to this technology the targeted delivery of the cytotoxic agent is enabled and the other toxicities on body are reduced. Ujvira is backed up with rigorous drug development programme. Patients already treated with Trastuzumab may still have the disease and would require this therapy as the next step. The high cost of therapy is a barrier to availing this therapy and Ujvira bridges this need
With more than 2.1 lakh new cases in 2020, Breast Cancer is the leading cancer in females in India and the risk increases with age. It is estimated that 1 in 29 women in India has a risk of developing Breast Cancer in her lifetime. Though rare, the incidence of HER2 Breast Cancer is also found in men. Other risk factors such as obesity, family history, genetics, alcohol, smoking, hormonal imbalance and improper diet have been identified as the contributing factors towards an increased incidence of Breast Cancer